Paul Bird1,2, Geoffrey Littlejohn1,3, Belinda Butcher4,5, Tegan Smith1, Candida da Fonseca Pereira6, David Witcombe6, Hedley Griffiths1,7. 1. OPAL Rheumatology Ltd, Sydney, New South Wales, Australia. 2. University of New South Wales, Kensington, New South Wales, Australia. 3. Monash University, Clayton, Victoria, Australia. 4. University of New South Wales, Kensington, New South Wales, Australia. bbutcher@writesourcemedical.com.au. 5. WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia. bbutcher@writesourcemedical.com.au. 6. Pfizer Australia, Sydney, New South Wales, Australia. 7. Barwon Rheumatology Service, Geelong, Victoria, Australia.
Abstract
INTRODUCTION: The aim of this study was to describe the real-world evidence for effectiveness, treatment persistence, and treatment patterns among patients in the community with rheumatoid arthritis treated with the JAK inhibitor tofacitinib. METHODS: This was a retrospective, non-interventional cohort study that extracted data for new users of tofacitinib or biologic disease-modifying antirheumatic drugs (bDMARDs) from the Australian Optimizing Patient outcomes in Australian RheumatoLogy (OPAL) dataset between March 2015 and September 2018. Patients were propensity score matched at a 1:2 tofacitinib to bDMARD ratio based on age, sex, and selected baseline treatment combinations. Treatment effectiveness was evaluated using disease status measures. Treatment persistence was calculated and the percentage of patients receiving monotherapy or combination therapy at treatment initiation was evaluated. RESULTS: Data from 2810 patients were extracted and 1950 patients were included in the matched population (1300 bDMARD initiators and 650 tofacitinib initiators). Patients were predominantly aged 55 to 74 years (57.8%) and female (81.2%). After 18 months of treatment, 52.4% and 57.8% of patients had achieved disease activity score (DAS) remission in the bDMARD and tofacitinib groups, respectively. The median treatment persistence for tofacitinib was similar to that for bDMARDs: 34.2 months (95% CI 32.2 to not reached) and 33.8 months (95% CI 28.8 to 40.4), respectively. In the overall population, more patients were prescribed tofacitinib as monotherapy (43.4%) compared with bDMARD monotherapy (33.4%). CONCLUSIONS: Tofacitinib demonstrated treatment effectiveness and persistence similar to bDMARDs. Overall, there was a trend for more use of tofacitinib as monotherapy than bDMARDs. Key Points • This study provides real-world evidence regarding effectiveness, treatment persistence, and treatment patterns, among patients with rheumatoid arthritis (RA) in the community being treated with tofacitinib. • The study suggests that tofacitinib is an effective and enduring intervention in RA with tofacitinib persistence and effectiveness comparable to bDMARDs.
INTRODUCTION: The aim of this study was to describe the real-world evidence for effectiveness, treatment persistence, and treatment patterns among patients in the community with rheumatoid arthritis treated with the JAK inhibitor tofacitinib. METHODS: This was a retrospective, non-interventional cohort study that extracted data for new users of tofacitinib or biologic disease-modifying antirheumatic drugs (bDMARDs) from the Australian Optimizing Patient outcomes in Australian RheumatoLogy (OPAL) dataset between March 2015 and September 2018. Patients were propensity score matched at a 1:2 tofacitinib to bDMARD ratio based on age, sex, and selected baseline treatment combinations. Treatment effectiveness was evaluated using disease status measures. Treatment persistence was calculated and the percentage of patients receiving monotherapy or combination therapy at treatment initiation was evaluated. RESULTS: Data from 2810 patients were extracted and 1950 patients were included in the matched population (1300 bDMARD initiators and 650 tofacitinib initiators). Patients were predominantly aged 55 to 74 years (57.8%) and female (81.2%). After 18 months of treatment, 52.4% and 57.8% of patients had achieved disease activity score (DAS) remission in the bDMARD and tofacitinib groups, respectively. The median treatment persistence for tofacitinib was similar to that for bDMARDs: 34.2 months (95% CI 32.2 to not reached) and 33.8 months (95% CI 28.8 to 40.4), respectively. In the overall population, more patients were prescribed tofacitinib as monotherapy (43.4%) compared with bDMARD monotherapy (33.4%). CONCLUSIONS:Tofacitinib demonstrated treatment effectiveness and persistence similar to bDMARDs. Overall, there was a trend for more use of tofacitinib as monotherapy than bDMARDs. Key Points • This study provides real-world evidence regarding effectiveness, treatment persistence, and treatment patterns, among patients with rheumatoid arthritis (RA) in the community being treated with tofacitinib. • The study suggests that tofacitinib is an effective and enduring intervention in RA with tofacitinib persistence and effectiveness comparable to bDMARDs.
Authors: Joel Kremer; Zhan-Guo Li; Stephen Hall; Roy Fleischmann; Mark Genovese; Emilio Martin-Mola; John D Isaacs; David Gruben; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; Tamas Koncz; Richard Riese; John Bradley Journal: Ann Intern Med Date: 2013-08-20 Impact factor: 25.391
Authors: Roy Fleischmann; Joel Kremer; John Cush; Hendrik Schulze-Koops; Carol A Connell; John D Bradley; David Gruben; Gene V Wallenstein; Samuel H Zwillich; Keith S Kanik Journal: N Engl J Med Date: 2012-08-09 Impact factor: 91.245
Authors: Roy Fleischmann; Eduardo Mysler; Stephen Hall; Alan J Kivitz; Robert J Moots; Zhen Luo; Ryan DeMasi; Koshika Soma; Richard Zhang; Liza Takiya; Svitlana Tatulych; Christopher Mojcik; Sriram Krishnaswami; Sujatha Menon; Josef S Smolen Journal: Lancet Date: 2017-06-16 Impact factor: 79.321
Authors: Gene V Wallenstein; Keith S Kanik; Bethanie Wilkinson; Stanley Cohen; Maurizio Cutolo; Roy Fleischmann; Mark C Genovese; Juan Gomez Reino; David Gruben; Joel Kremer; Sriram Krishnaswami; Eun Bong Lee; Virginia Pascual-Ramos; Vibeke Strand; Samuel H Zwillich Journal: Clin Exp Rheumatol Date: 2016-04-28 Impact factor: 4.473
Authors: Gerd R Burmester; Ricardo Blanco; Christina Charles-Schoeman; Jürgen Wollenhaupt; Cristiano Zerbini; Birgitta Benda; David Gruben; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; Tamas Koncz; Koshika Soma; John Bradley; Charles Mebus Journal: Lancet Date: 2013-01-05 Impact factor: 79.321
Authors: Désirée van der Heijde; Yoshiya Tanaka; Roy Fleischmann; Edward Keystone; Joel Kremer; Cristiano Zerbini; Mario H Cardiel; Stanley Cohen; Peter Nash; Yeong-Wook Song; Dana Tegzová; Bradley T Wyman; David Gruben; Birgitta Benda; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; John D Bradley; Carol A Connell Journal: Arthritis Rheum Date: 2013-03
Authors: Eun Bong Lee; Roy Fleischmann; Stephen Hall; Bethanie Wilkinson; John D Bradley; David Gruben; Tamas Koncz; Sriram Krishnaswami; Gene V Wallenstein; Chuanbo Zang; Samuel H Zwillich; Ronald F van Vollenhoven Journal: N Engl J Med Date: 2014-06-19 Impact factor: 91.245
Authors: Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde Journal: Ann Rheum Dis Date: 2015-05-12 Impact factor: 19.103
Authors: Stanley B Cohen; Yoshiya Tanaka; Xavier Mariette; Jeffrey R Curtis; Eun Bong Lee; Peter Nash; Kevin L Winthrop; Christina Charles-Schoeman; Krishan Thirunavukkarasu; Ryan DeMasi; Jamie Geier; Kenneth Kwok; Lisy Wang; Richard Riese; Jürgen Wollenhaupt Journal: Ann Rheum Dis Date: 2017-01-31 Impact factor: 19.103
Authors: Andrei Barbulescu; Johan Askling; Katerina Chatzidionysiou; Helena Forsblad-d'Elia; Alf Kastbom; Ulf Lindström; Carl Turesson; Thomas Frisell Journal: Rheumatology (Oxford) Date: 2022-10-06 Impact factor: 7.046